Pfizer-BioNTech partner with Biovac for Covid vaccine manufacturing and distribution
Per agreement, facility will be producing over 100 million doses annually for use in African Union
Pfizer and BioNTech have signed a letter of intent with The Biovac Institute (Pty) Ltd (Biovac), a biopharma company based in Capetown, South Africa, to manufacture and distribute their Covid-19 vaccine for distribution in the African Union.
Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s global Covid-19 vaccine supply chain and manufacturing network, which will now span across three continents and include more than 20 manufacturing facilities. Technical transfer, on-site development and equipment installation activities will begin immediately.
Pfizer and BioNTech expect that Biovac’s Cape Town facility will be incorporated into the vaccine supply chain by the end of this year. Biovac will obtain drug substance from facilities in Europe, and manufacturing of finished doses will begin in 2022. At full operational capacity, the annual production will exceed 100 million finished doses annually. All doses will exclusively be distributed within the 55 member states that comprise the African Union.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
